Gluconate Compositions for Neonatal Seizure Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current antiepileptic drugs are ineffective in treating neonatal seizures, as they often exacerbate the condition or have severe side effects, and there is a need for a safe and effective treatment that targets the unique characteristics of neonatal epilepsy.

Innovation Solution

The use of gluconate-based and glucose oxidase compositions, which convert glucose into gluconate, effectively reducing convulsions in neonates by blocking CLC-3 chloride channels, providing a potent and selective therapy for neonatal epilepsy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current antiepileptic drugs are used to treat neonatal seizures, then GABAA-R function is increased, but seizure activity is exacerbated due to excitatory GABAergic transmission in the developing brain

Engineering Contradiction:

Improveeffectiveness of antiepileptic drugsVSAvoidexacerbation of seizure activity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Instead of enhancing GABAergic inhibition (the conventional approach), the patent inverts the strategy by blocking excitatory GABAA-R transmission. This is achieved through specific antagonists that selectively inhibit the excitatory pathway in the developing brain, thereby treating seizures without exacerbating them.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent applies local quality by targeting specific GABAA-R subtypes or locations that mediate excitatory transmission in the developing brain, rather than broadly enhancing all GABAergic activity. This selective blockade allows treatment of seizures while preserving necessary inhibitory function.

Inventive Principle:

Principle #3Local quality

2Ease of operation

If GABA agonists are administered to control neonatal seizures, then GABAA-R function is enhanced, but neonatal seizure activity is worsened

Engineering Contradiction:

Improvesimplicity of treatment approachVSAvoidefficacy in controlling seizures

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent inverts the conventional approach by using GABAA-R antagonists instead of agonists. This simple conceptual reversal—blocking rather than enhancing GABAergic transmission—addresses the unique pathophysiology of neonatal seizures where GABA is excitatory rather than inhibitory.

Inventive Principle:

Principle #13The other way round (Inversion)

3Reliability

If NKCC1 blocker bumetanide is used to treat neonatal seizures, then chloride transport is inhibited, but severe side effects occur and treatment effect is limited

Engineering Contradiction:

Improveeffectiveness of NKCC1 blockadeVSAvoidsevere side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the therapeutic benefit of chloride transport inhibition while eliminating the harmful side effects by using GABAA-R antagonists instead of NKCC1 blockers. This approach selectively targets the excitatory GABAergic transmission pathway without disrupting overall chloride homeostasis or causing systemic side effects.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses GABAA-R antagonists as intermediaries to achieve the therapeutic goal of reducing excitatory GABAergic transmission. These antagonists mediate the effect by selectively binding to and blocking the excitatory GABAA-R subtype, providing a more selective and safer approach compared to broad NKCC1 inhibition.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Gluconate compositions significantly suppress neonatal epileptic activity with minimal side effects, offering a more effective treatment than existing antiepileptic drugs, particularly in inhibiting CLC-3 chloride channels and reducing seizure burden in neonates.

Implementation Method 1

a composition comprising glucose oxidase... under conditions such that said convulsions are reduced. In one embodiment, said conditions comprise the conversion of said glucose into gluconate

Methodology Applied

Scientific EffectOxidation: Oxidation

Data Source

PatentUS11666640B2Glucose oxidase compositions as a neonate anticonvulsant

Publication Date: 2023.06.06 THE PENN STATE RES FOUND INC

AI summary

Neonatal seizure is different from adult seizure, and many anti epileptic drugs that are effective in adults often fail to treat neonatal seizure. Gluconic acid, a natural organic acid enriched in fruits and honey, and the glucose oxidase enzyme, is shown herein to potently inhibit neonatal epilepsy both in vitro and in vivo. Sodium gluconate is shown to inhibit epileptiform burst activity in cell cultures and protect neurons from kainic acid-induced cell death. Sodium gluconate also inhibited epileptiform burst activity in brain slices in a manner that was much more potent in neonatal animals than in older animals. Consistently, in vivo EEC recordings also revealed that sodium gluconate inhibited the epileptic seizure activity in a manner that was much more potent in neonates than in adult animals. Mechanistically, sodium gluconate inhibits voltage-dependent CLC-3 C1− channels both in neuronal cultures and in hippocampal slices. Together, these data suggest a novel antiepileptic drug gluconate that potently inhibits neonatal seizures through blocking CLC-3 C1− channels.